Want to see JP:6190 full AI Analyst Report?

PhoenixBio Co., Ltd. (6190) Price & Analysis

0 Followers

6190 Stock Chart & Stats

¥484.00

¥9.00(2.79%)

At close: Jan 08 4:00 PM EST

¥484.00

¥9.00(2.79%)

Day’s Range― - ―

52-Week Range¥321.00 - ¥724.00

Previous CloseN/A

Volume3.50K

Average Volume (3M)5.08K

Market Cap

¥1.39B

Enterprise Value¥659.26

Total Cash (Recent Filing)¥1.15B

Total Debt (Recent Filing)¥486.64M

Price to Earnings (P/E)91.8

Beta0.49

Next Earnings

Nov 18, 2026

EPS EstimateN/A

Next Dividend Ex-DateN/A

Dividend YieldN/A

Share Statistics

EPS (TTM)30.80

Shares Outstanding4,076,933

10 Day Avg. Volume5,730

30 Day Avg. Volume5,083

Financial Highlights & Ratios

PEG Ratio-0.11

Price to Book (P/B)1.15

Price to Sales (P/S)1.14

P/FCF Ratio31.70

Enterprise Value/Market CapN/A

Enterprise Value/RevenueN/A

Enterprise Value/Gross ProfitN/A

Enterprise Value/EbitdaN/A

Forecast

1Y Price TargetN/A

Price Target UpsideN/A

Rating ConsensusN/A

Number of Analyst Covering0

EPS Forecast (FY)N/A

Revenue Forecast (FY)N/A

Bulls Say, Bears Say

Bulls Say

Earnings RecoveryThe return to profitability improves internal funding capacity and demonstrates that demand and operating execution can support earnings recovery, although continued delivery is needed to establish that the improvement is durable.

Strong Gross MarginA high gross margin indicates meaningful value in PhoenixBio’s specialized preclinical services and can provide operating leverage as study volumes grow, supporting resilience if the company sustains pricing and utilization.

Proprietary CRO PlatformThe proprietary humanized-liver model gives PhoenixBio a differentiated basis for PK, DMPK, efficacy, and safety studies, potentially supporting repeat pharmaceutical and biotechnology customer demand.

Bears Say

Weak Cash ConversionLimited conversion of reported earnings into operating cash reduces the quality of profitability and may constrain reinvestment or working-capital flexibility until cash generation becomes consistently stronger.

Earnings VolatilityLarge swings between profit and loss make future earnings less predictable and weaken confidence in the durability of the latest recovery, especially for a project-based CRO exposed to study timing.

Inconsistent Revenue TrendThe conflicting and weak broader revenue trend suggests that the latest increase may not yet represent sustained expansion, leaving growth dependent on securing a steadier pipeline of customer studies.

6190 FAQ

What was PhoenixBio Co., Ltd.’s price range in the past 12 months?

PhoenixBio Co., Ltd. lowest stock price was ¥321.00 and its highest was ¥724.00 in the past 12 months.

What is PhoenixBio Co., Ltd.’s market cap?

PhoenixBio Co., Ltd.’s market cap is ¥1.39B.

When is PhoenixBio Co., Ltd.’s upcoming earnings report date?

PhoenixBio Co., Ltd.’s upcoming earnings report date is Nov 18, 2026 which is in 75 days.

How were PhoenixBio Co., Ltd.’s earnings last quarter?

PhoenixBio Co., Ltd. released its earnings results on Aug 14, 2026. The company reported -¥22.38 earnings per share for the quarter.

Is PhoenixBio Co., Ltd. overvalued?

According to Wall Street analysts PhoenixBio Co., Ltd.’s price is currently Overvalued. Get more investment ideas with TipRanks Premium

Does PhoenixBio Co., Ltd. pay dividends?

PhoenixBio Co., Ltd. does not currently pay dividends.

What is PhoenixBio Co., Ltd.’s EPS estimate?

PhoenixBio Co., Ltd.’s EPS estimate for its next earnings report is not yet available.

How many shares outstanding does PhoenixBio Co., Ltd. have?

PhoenixBio Co., Ltd. has 4,076,933 shares outstanding.

What happened to PhoenixBio Co., Ltd.’s price movement after its last earnings report?

PhoenixBio Co., Ltd. reported an EPS of -¥22.38 in its last earnings report. Following the earnings report the stock price went down -0.284%.

Which hedge fund is a major shareholder of PhoenixBio Co., Ltd.?

Currently, no hedge funds are holding shares in JP:6190

What is the TipRanks Smart Score and how is it calculated?

Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology

Company Description

PhoenixBio Co., Ltd.

PhoenixBio Co., Ltd. delivers specialized contract research services to support drug discovery and development, with a primary focus on the Japanese market. Central to its offerings is the proprietary PXB-mouse, a unique chimeric mouse model featuring a humanized liver, which is critical for various drug development experiments. The company also conducts in vitro analyses utilizing fresh human hepatocytes sourced from PXB-cells. This sophisticated humanized liver model proves invaluable for in vivo studies encompassing gene therapy, NASH/NAFLD drug development programs, anti-viral therapeutic evaluations, DMPK (Drug Metabolism and Pharmacokinetics) and toxicity assessments, and custom transplantation projects. Established in 2002, PhoenixBio maintains its headquarters in Higashihiroshima, Japan.